Background: The devastating effects of heavy alcohol drinking have been long time recognized. In the last decades, potential benefits of modest red wine drinking were suggested. In European countries in which red wide intake is not negligible (such as France), the association between cholesterol and cardiovascular (CV) risk was less evident, suggesting the action of some protective molecules in red wine or other foods and drinks.
Methods: This narrative review is based on the material searched for and obtained via PubMed up to May 2016. The search terms we used were: “red wine, cardiovascular, alcohol” in combination with “polyphenols, heart failure, infarction”.
Results: Epidemiological and mechanistic evidence of a J-shaped relationship between red wine intake and CV risk further supported the “French paradox”. Specific components of red wine both in vitro and in animal models were discovered. Polyphenols and especially resveratrol largely contribute to CV prevention mainly through antioxidant properties. They exert beneficial effects on endothelial dysfunction and hypertension, dyslipidemia, metabolic diseases, thus reducing the risk of adverse CV events such as myocardial infarction ischemic stroke and heart failure. Of interest, recent studies pointed out the role of ethanol itself as a potential cardioprotective agent, but a clear epidemiological evidence is still missing. The aim of this narrative review is to update current knowledge on the intracellular mechanism underlying the cardioprotective effects of polyphenols and ethanol. Furthermore, we summarized the results of epidemiological studies, emphasizing their methodological criticisms and the need for randomized clinical trials able to clarify the potential role of red wine consumption in reducing CV risk.
Conclusion: Caution in avowing underestimation of the global burden of alcohol-related diseases was particularly used.
Keywords: Alcohol, ethanol, flavonoids, polyphenols, red wine, resveratrol.
Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia
Current Pharmaceutical Design Role of Renin-Angiotensin System in Vascular Endothelial Dysfunction of Pregnancy-Induced Hypertension
Current Hypertension Reviews New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Renal Effects of Non-Steroidal Anti-Inflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors
Current Pharmaceutical Design Structure-Based Discovery of PDEs Inhibitors
Current Topics in Medicinal Chemistry Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Mineralocorticoid Receptor-Associated Hypertension and Target Organ Damage: Clinical Relevance for Resistant Hypertension in End Stage Renal Disease
Current Hypertension Reviews Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Measurement of Cerebral Blood Flow with Near Infrared Spectroscopy and Indocyanine Green Dye Dilution
Current Medical Imaging Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Epidemiological and Clinical Evidence on the Relationship Between Mediterranean Diet and the Metabolic Syndrome
Current Nutrition & Food Science Effects of Cholinergic Enhancing Drugs on Cholinergic Transporters in the Brain and Peripheral Blood Lymphocytes of Spontaneously Hypertensive Rats
Current Alzheimer Research Adverse HBOC-Endothelial Dysfunction Synergism: A Possible Contributor to Adverse Clinical Outcomes?
Current Drug Discovery Technologies Pharmacological Potential of Exercise and RAS Vasoactive Peptides for Prevention of Diseases
Current Protein & Peptide Science New Insight into Urate-Related Mechanism of Cardiovascular Damage
Current Pharmaceutical Design Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension
Current Vascular Pharmacology Human Liver Enzymes Responsible for Metabolic Elimination of Tyramine, a Vasopressor Agent from Daily Food
Drug Metabolism Letters Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders